跳至主要内容
临床试验/NCT03428048
NCT03428048招募中不适用

NEXUS Registry: An Outcomes Database Which Tracks Patient -Reported Outcomes After Percutaneous Coronary Intervention for Coronary Artery Disease Along With Surgical and Subcutaneous Ablation for the Management of Atrial Fibrillation.

Cardiovascular Innovation and Research Institute1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
1
主要终点
Change from baseline in Veterans Rand (VR) 12

研究概览

简要总结

Information gathered from the patients via a disease specific questionnaire will be married to data from the National Cardiovascular Data Registry (NCDR®). Details will be continuously analyzed and used to direct quality of care at our center. The institution is categorized as a low-volume institution for percutaneous coronary intervention (PCI) for coronary artery disease treatment as well as surgical and endocardial ablation for the management of atrial fibrillation (Afib). The association between operator volume and quality has primarily focused on rare complications, such as mortality. The aim is to highlight the advantages of receiving care close to home. A benefit of offering the procedures to treat diseases at centers that have lower volumes is to improve patients' outcomes while also providing more convenient access to quality care. The key outcome from the patients' experience is alleviation of their symptoms while increasing function and quality of life. To date, there have been no studies documenting the health status benefits of PCI and surgical / endocardial ablation for coronary artery disease and Afib, respectively with low- volume operators. In this study, the investigators sought to examine the feasibility of implementing patient-reported outcomes into clinical care and to demonstrate evidence of benefits, from patients' perspectives, of receiving treatment by low-volume operators.

详细描述

This is a prospective cohort, time series analysis of the routine procedures associated with the catheterization and the electrophysiology lab through ten years post intervention. The goal is to demonstrate clinical effectiveness with cardiac service line with low-volume operators. A connection between NCDR with applied clinical research that directs continuous quality improvement goals and objectives is the ideal setting for value-based, quality care. The system of diagnosing, treating and tracking individuals with cardiovascular and pacing disease has many facets which could benefit from continuous quality improvement and outcomes analysis. The proposed Valley View NEXUS outcomes registry will bridge national data to local clinical data. Clinical registries are a methodically sound instrument for measuring and improving performance. Registries are efficacious for surveillance, measuring effectiveness of quality improvement initiatives, identifying determinates of quality of life and function while synergistically increasing the value of health care expenditures with respect to heart disease, stroke, and arrhythmias.

The ADVARRA formerly Schulman Institutional Review Board (IRB) reviewed our protocol, and authorized the study. Once informed consent was obtained, eligible adults scheduled for diagnostic angiography with possible PCI completed a baseline patient reported outcome assessment and again at designated follow-up intervals (six months and annually thereafter for up to ten years). Due to the urgent nature of STEMI- PCI procedures, it was determined that informed consent prior to PCI was prohibitive; however after consideration, the protocol was amended to capture baseline assessments immediately following PCI while the patient 's status was in hospital with use of the Seattle Angina Questionnaire (SAQ) and the Veterans Rand 12-Item Health Survey (VR-12). The SAQ is recognized as a disease specific questionnaire for coronary artery disease. The SAQ is a six item questionnaire that assesses patient's function, symptoms, and satisfaction. A higher score translates to better outcomes. The VR-12 is a twelve item questionnaire used to assess quality of life. A lower score translates to a higher quality of life in relation to a person's health and wellness. Combining data from a disease specific questionnaire, quality of life assessment, and the NCDR's CathPCI® Registry serves as a nexus between big data and the individual patient experience. From January 2015 through December 2017, twenty- two patients have been enrolled. Based on the data from the first six patients to provide scores both at baseline and month six and with a study design to have 90% power to detect a change in the overall SAQ score of 10 points at six months, it was determined 49 patients will need to be enrolled.

The aforementioned methodology will be applied for surgical and endocardial ablations for patients' with Afib. Presently, enrollment is open for Afib patients and data being captured will be analyzed to determine sample size. Patients who receive intervention for management Afib will complete the Atrial Fibrillation Effect on Quality -of-life (AFEQT) Questionnaire and the VR-12. Again the VR-12 is a twelve item questionnaire used to assess quality of life. A lower score translates to a higher quality of life in relation to a person's health and wellness. The AFEQT is recognized as a disease specific questionnaire for Afib. A higher score translates to worse symptoms and limitations in daily function associated with Afib. Combining the outcomes metric with NCDR's Afib Ablation Registry ® allows our institution demonstrative effective outcomes for low-volume operators.

The data validation process applies to both PCI and surgical and/or endocardial ablation and is as follows:

  1. Quality Assurance Plan Training for staff that populates both data registries is ongoing. Staff will participate in the NCDR® applicable training modules. Documentation of training will be maintained in the study coordinator's office. Agreeing to participate with the NCDR®, an institution also agrees to random site monitoring and/or audits.
  2. Data Checks All patients who agree to participate in NEXUS outcomes registry and subsequent statistical analysis will experience a complete date audit for both outcomes assessments and NCDR® data elements. NCDR® has algorithm limits for both CathPCI® Registry and Afib Ablation ® Registry. All registry elements require abstraction form Meditech source documents. Reports are titled Cardiology Procedure Note and Electrophysiology Procedure Note for PCI and Afib ablation, respectively. Quality/outcome metrics will be sampled in paper form -the sources documents. Information will then be populated into excel for scoring. All paper forms will be maintained for the life of the study.
  3. Data Dictionary Complete Data Dictionaries are provided by NCDR® with data element numbers and associated limits and acceptable values for both Cath PCI ® and Afib Ablation ® Registry.
  4. Standard Operating Procedures A complete NEXUS Registry Protocol will be on site held in the Cardiovascular Innovation & Research Institute at Valley View Hospital along with all regulatory information, lab certifications, training documents, IRB documents, license agreements, analytic agreements and process maps for informed consent for outcomes research. Note NCDR® registries obtained a waiver for informed consent.
  5. Sample Size Assessment The number of patients necessary to demonstrate an effect for outcomes after PCI with low-volume operators is 49.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Candidates will be included in the study only if all the following conditions are met:
  • Age >18 years
  • The subject has been informed of the nature of the study, agrees to its provisions, is able to comprehend, and has provided informed consent.
  • The subject is available for follow-up.
  • The subject has a diagnosis of coronary artery disease or Afib.

排除标准

  • Candidates will be excluded from the study if any of the following conditions are present:
  • Failure and / or inability and / or unwillingness to provide informed consent.
  • Likely problems, in the judgement of the investigators, with maintaining follow-up.

结局指标

主要结局

Change from baseline in Veterans Rand (VR) 12

时间窗: Initial analysis at baseline (administered pre-AF intervention) to follow-up intervals at 6 months and annually thereafter up to 10 years

The VR 12 is a 12-item health survey, validated quality of life questionnaire- open source

Change from baseline in Atrial Fibrillation Effect on Quality -of-Life (AFEQT) questionnaire at designated follow-up intervals

时间窗: Initial Analysis at baseline (administered pre-AF intervention) to follow-up intervals at 6 months and then annually thereafter up to 10 years

The AFEQT is a validated disease specific questionnaire used for assessing clinical disease impact on ADLs, emotional status, satisfaction with treatment and quality of life.

Number of patients that experience a re-admit status post intervention

时间窗: Within 90 days post intervention

The number of patients that are re-admitted with a Serious Adverse Event (SAE) or Adverse Event (AE) as a result of their index procedure

次要结局

  • Number of patients that are in sinus rhythm post AF intervention(Assessed 6 months post procedure and annually thereafter)
  • number of patients on anti-arrhythmic agents post intervention(After 3 months post intervention /ablation known as blanking period and measured annually thereafter)

研究者

发起方
Cardiovascular Innovation and Research Institute
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Lupus Landmark Study: A Prospective Registry and BiorepositorySystemic Lupus Erythematosus (SLE)Neuropsychiatric Systemic Lupus ErythematosusLupus Nephritis
NCT05934149Lupus Research Alliance3,500
已完成
不适用
Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and DiseaseCorneal DiseaseEndothelial Corneal DystrophyCorneal Transplant FailureCorneal Transplant Rejection
NCT06101017Nitin Vaswani19
招募中
不适用
Innovations in Genicular Outcomes RegistryKnee Osteoarthritis
NCT05495334Pacira Pharmaceuticals, Inc10,000
已完成
不适用
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque PsoriasisModerate to Severe Plaque Psoriasis
NCT01555606Janssen Biotech, Inc.108
招募中
不适用
AnovaOS Network Powered Patient RegistryInfectious DiseaseNeoplasmsDiseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89)Endocrine, Nutritional and Metabolic Diseases (E00-E89)Mental and Behavioural DisordersDiseases of the Nervous SystemDiseases of the Eye and AdnexaDiseases of the Ear and Mastoid ProcessDiseases of the Circulatory SystemDiseases of the Respiratory SystemDiseases of the Digestive SystemDiseases of the Skin and Subcutaneous TissueDiseases of the Musculoskeletal System and Connective TissueDiseases of the Genitourinary SystemPregnancy, Childbirth and the PuerperiumCertain Conditions Originating in the Perinatal PeriodCongenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99)Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere ClassifiedInjury, Poisoning and Certain Other Consequences of External CausesExternal Causes of Morbidity and MortalityFactors Influencing Health Status and Contact With Health Services
NCT05013944Anova Enterprises, Inc100,000